Mural Oncology Pivots with $144.4M War Chest, Eyes Strategic Deals After Nemvaleukin Halt

Stock Information for Mural Oncology plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Mural Oncology plc

Mural Oncology Announces Plans to Explore Strategic Alternatives
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones
Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.